Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study

Evidence of the Clinical Efficacy of Antiviral Agents against SARS-CoV-2

“…The WHO's pivotal SOLIDARITY trial (n= 2 743) found that RDV treatment had no real effects on mortality or the course of the disease and did not show overall efficacy [24]. This study, supported by two other smaller studies, including a nor-solidarity trial, provided sufficient evidence to conclude that RDV has little efficacy to offer [22,23]. Some improvement was seen when combining RDV with barcitinab, but this was not convincing [21].…”

“…Eight RCTs, including the WHO's SOLIDARITY trial, involving a total of 4 829 patients, have tested the efficacy of RDV (Table 1). Early studies, [17][18][19][20] showed promising results while later larger trials, [21][22][23][24] disputed these findings. Initial trials indicated that RDV showed potential, most notably in studies conducted by Wang et al and Beigel et al [17,18].…”

Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review

“…The RCT has been conducted by The Adaptive COVID-19 Treatment Trial (ACTT) showed shortened duration of disease course and mortality reduction in patients who needed supplemental oxygen [23]. Conversely, another large international, multi-arm, RCT named "Solidarity" [24] and other RCTs [25,26] has not reported an overall reduction in mortality of COVID-19 hospitalized patients who received remdesivir. Overall, Solidarity has not reported mortality benefit, shortened time to discharge or ventilation requirement reduction following the administration of remdesivir.…”

Update Alert: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)

“…The living, rapid systematic review identified 1 new randomized controlled trial that met inclusion criteria, comparing a 5-day course of remdesivir to standard care in adults hospitalized with COVID-19 not requiring invasive ventilation at baseline (5). The new study, however, was determined to be of poor quality (high risk of bias).…”

“…This is an update of the American College of Physicians' living, rapid practice points about using remdesivir for treatment of COVID-19 (1), which is based on an updated systematic review done through 10 May 2021 (2)(3)(4). The evidence update identified 1 new study that could inform Practice Point 1 (5). No new studies were identified as supporting evidence for Practice Points 2 or 3.…”